See more : Oroco Resource Corp. (OCO.V) Income Statement Analysis – Financial Results
Complete financial analysis of ORIC Pharmaceuticals, Inc. (ORIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ORIC Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- D.P. Wires Limited (DPWIRES.BO) Income Statement Analysis – Financial Results
- PT Kino Indonesia Tbk (KINO.JK) Income Statement Analysis – Financial Results
- MultiQ International AB (publ) (MULQ.ST) Income Statement Analysis – Financial Results
- Centro HL Distribuzione S.p.A. (CHL.MI) Income Statement Analysis – Financial Results
- Grandjoy Holdings Group Co., Ltd. (000031.SZ) Income Statement Analysis – Financial Results
ORIC Pharmaceuticals, Inc. (ORIC)
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| Gross Profit | -1.03M | -966.00K | -897.00K | -970.00K | -1.00M | -900.00K | -900.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 85.17M | 61.68M | 56.86M | 35.92M | 22.84M | 19.03M | 19.13M |
| General & Administrative | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 3.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -900.00K |
| SG&A | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 2.52M |
| Other Expenses | 0.00 | 5.00M | 15.00K | 177.00K | 289.00K | 233.00K | 0.00 |
| Operating Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 21.64M |
| Cost & Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 22.54M |
| Interest Income | 10.08M | 2.65M | 141.00K | 306.00K | 1.40M | 775.00K | 251.00K |
| Interest Expense | 0.00 | 2.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| EBITDA | -109.75M | -91.77M | -77.97M | -74.19M | -27.54M | -20.46M | -21.13M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -110.78M | -91.77M | -78.87M | -74.19M | -28.57M | -22.37M | -22.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.08M | 2.65M | 156.00K | 483.00K | 1.69M | 1.01M | 512.00K |
| Income Before Tax | -100.70M | -89.12M | -78.72M | -73.70M | -26.88M | -21.36M | -22.03M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.36M | -1.04M | 23.57M | -1.40M | -1.01M | 0.00 |
| Net Income | -100.70M | -91.48M | -77.68M | -97.27M | -25.49M | -21.36M | -22.03M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EPS Diluted | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| Weighted Avg Shares Out | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
| Weighted Avg Shares Out (Dil) | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Source: https://incomestatements.info
Category: Stock Reports